Normal view
-
cs.AI, q-bio.NC updates on arXiv.org
-
GLARE: Generative Learning via Adversarial Reward Estimation For Social Dynamics Forecasting
arXiv:2609.12165v1 Announce Type: new Abstract: Meeting continuation requires tracking the agenda, speaker roles, participant intentions, and disagreement across long multi-party discussions. We introduce the Meeting Dynamic Forecasting Benchmark (MDFB), constructed from 2,207 real-world meetings and 24,794 future-facing queries. Given a transcript prefix and an active question, a model generates a plausible multi-turn continuation in one call. We evaluate utility---progress toward the question
-
cs.AI, q-bio.NC updates on arXiv.org
-
LifeFuse-Mem: Lifecycle-Aware State Fusion Against Temporary Overwriting for Long-Term Memory
arXiv:2609.12436v1 Announce Type: new Abstract: Long-running LLM agents require memory mechanisms that maintain coherent internal states across interactions. We study a lifecycle-labeled memory setting in which write episodes provide lifecycle metadata during training, and phase-aware readout is used during evaluation. This setting reflects the need to distinguish information that should remain influential across future interactions from information that should affect only the current context.
LifeFuse-Mem: Lifecycle-Aware State Fusion Against Temporary Overwriting for Long-Term Memory
-
cs.AI, q-bio.NC updates on arXiv.org
-
Beyond Generation and Accuracy: Diagnosing and Enhancing Visual Chain-of-Thought for Geometry Problem Solving
arXiv:2609.12606v1 Announce Type: new Abstract: While multimodal reasoning has advanced rapidly, solving complex geometry problems critically hinges on active visual assistance, such as constructing auxiliary lines, spurring the rise of Visual Chain-of-Thought (VCoT). However, existing evaluations typically assess visual generation quality and final answer accuracy in isolation, failing to examine whether intermediate visual aids are geometrically valid, effectively utilized in subsequent reaso
Beyond Generation and Accuracy: Diagnosing and Enhancing Visual Chain-of-Thought for Geometry Problem Solving
-
cs.AI, q-bio.NC updates on arXiv.org
-
MedCollab: IBIS-Guided Multi-Agent Collaboration with Hierarchical Disease Relation Chains for Clinical Diagnosis
arXiv:2603.01131v4 Announce Type: replace-cross Abstract: Clinical diagnosis is a gradual process of evidence integration, in which physicians move from symptoms and medical history to examinations, competing hypotheses, disease relations, and treatment decisions. Large language models have advanced medical text understanding and generation. Yet their clinical use remains limited by weak evidence grounding, opaque reasoning, and inconsistent links among differential diagnosis, final diagnosis,
MedCollab: IBIS-Guided Multi-Agent Collaboration with Hierarchical Disease Relation Chains for Clinical Diagnosis
-
Omics In Lung
-
Narrative review of the staging classification controversy in stage N3 small cell lung cancer: from the perspective of overlapping Veterans Administration Lung Study Group and International Association for the Study of Lung Cancer definitions
J Thorac Dis. 2026 Aug 31;18(8):950. doi: 10.21037/jtd-2026-1704. Epub 2026 Aug 28.ABSTRACTBACKGROUND AND OBJECTIVE: Traditionally, two primary systems have been employed for staging small cell lung cancer (SCLC): the Veterans Administration Lung Study Group (VALG) system and the International Association for the Study of Lung Cancer (IASLC) tumor, node, metastasis (TNM) system. The term "limited disease" is defined differently: VALG characterizes it as disease encompassed within a single tolera
Narrative review of the staging classification controversy in stage N3 small cell lung cancer: from the perspective of overlapping Veterans Administration Lung Study Group and International Association for the Study of Lung Cancer definitions
J Thorac Dis. 2026 Aug 31;18(8):950. doi: 10.21037/jtd-2026-1704. Epub 2026 Aug 28.
ABSTRACT
BACKGROUND AND OBJECTIVE: Traditionally, two primary systems have been employed for staging small cell lung cancer (SCLC): the Veterans Administration Lung Study Group (VALG) system and the International Association for the Study of Lung Cancer (IASLC) tumor, node, metastasis (TNM) system. The term "limited disease" is defined differently: VALG characterizes it as disease encompassed within a single tolerable radiation field, while IASLC defines it as the lack of distant metastases (M0). Patients with N3 disease frequently satisfy VALG extensive-stage (ES) criteria while meeting IASLC limited-stage (LS) criteria, resulting in a notable staging discrepancy. Therefore, this review aims to clarify the clinical challenges posed by this staging overlap and provide insights for standardizing staging terminology and optimizing therapeutic decision-making in N3 SCLC.
METHODS: A narrative review utilizing a systematized search strategy was conducted. While strict adherence to PRISMA guidelines was not pursued because the extensive heterogeneity of the literature precluded a formal meta-analysis, rigorous search criteria were applied to minimize selection bias. Databases including PubMed, Web of Science, Embase, the Cochrane Library, and China National Knowledge Infrastructure (CNKI) were searched for literature from January 2000 to March 2026. Studies examining stage N3 SCLC, spatial metastatic burden, and definitional inconsistencies between the VALG and IASLC staging systems were analyzed to assess their effects on treatment dosimetry, systemic therapy, and survival outcomes.
KEY CONTENT AND FINDINGS: The staging overlap in N3 SCLC leads to heterogeneous clinical management depending on its spatial metastatic burden, and this highly variable cohort can be stratified into distinct prognostic subgroups based on the anatomical distribution (single-region vs. multi-region) of the involved lymph nodes.
CONCLUSIONS: These findings should guide clinical trial design and terminology. Clinical decision-making must transcend historical paradigms and technical constraints. Future strategies must incorporate spatial evaluations of metastatic burden alongside innovative multimodal tools, such as artificial intelligence (AI) and multi-omics, to facilitate tailored therapy for SCLC.
PMID:42724560 | PMC:PMC13559235 | DOI:10.21037/jtd-2026-1704